AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 25900643 — intervention group
Group type: EXPERIMENTAL
Intervention: 1000 mg intravenous iron isomaltoside 1000 administered perioperatively by infusion
Number of subjects: 60
Study 25900643 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 60
Study 24494291 — intervention group
Group type: EXPERIMENTAL
Intervention: Longhu Jiaozhan manipulation
Number of subjects: 62
Study 24494291 — intervention group
Group type: COMPARATOR
Intervention: Even manipulation (control group)
Number of subjects: 62
Study 24494291 — intervention group
Group type: EXPERIMENTAL
Intervention: Both methods of acupuncture
Number of subjects: 62
Study 21627398 — intervention group
Group type: COMPARATOR
Intervention: Standard triple drug therapy (omeprazole, clarithromycin, and amoxicillin for 10 days)
Number of subjects: 73
Study 21627398 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequential therapy (omeprazole and amoxicillin for the first 5 days followed by omeprazole, clarithromycin, and amoxicillin for the next 5 days)
Number of subjects: 73
Study 19751435 — intervention group
Group type: EXPERIMENTAL
Intervention: Helicobacter pylori infection
Number of subjects: 2361
Study 17355820 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive graft perfusion (PGP, n = 15) during anastomosis and immediate graft perfusion after distal anastomosis.
Number of subjects: 30
Study 17355820 — intervention group
Group type: EXPERIMENTAL
Intervention: Passive graft perfusion (PGP, n = 15)
Number of subjects: 30
Study 17355820 — intervention group
Group type: COMPARATOR
Intervention: No graft perfusion (NGP, n = 15)
Number of subjects: 30
Study 15211234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristinamycin 3 G daily for 4 days
Number of subjects: 476
Study 15211234 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav 2 G daily for 8 days
Number of subjects: 476
Study 15211234 — intervention group
Group type: EXPERIMENTAL
Intervention: Pristinamycin
Number of subjects: 476
Study 15211234 — intervention group
Group type: COMPARATOR
Intervention: Co-amoxiclav
Number of subjects: 476
Study 11683127 — intervention group
Group type: EXPERIMENTAL
Intervention: Lasoprol (test formulation)
Number of subjects: 12
Study 11683127 — intervention group
Group type: COMPARATOR
Intervention: Lanzor (reference formulation)
Number of subjects: 12
Study 9645593 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone dipropionate (BDP), 400 microg twice a day
Number of subjects: 24
Study 7840912 — intervention group
Group type: EXPERIMENTAL
Intervention: Interferon-alpha
Number of subjects: 180
Study 3277587 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipenem-cilastatin
Number of subjects: 57
Study 3277587 — intervention group
Group type: COMPARATOR
Intervention: Clindamycin and Gentamicin
Number of subjects: 57
Study 30059785 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant (1 or 2 doses)
Number of subjects: 43
Study 30059785 — intervention group
Group type: COMPARATOR
Intervention: Placebo (air)
Number of subjects: 43
Study 30059785 — intervention group
Group type: EXPERIMENTAL
Intervention: Calfactant
Number of subjects: 43
Study 27549242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (n = 45)
Number of subjects: 93
Study 27549242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 48)
Number of subjects: 93
Study 27549242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (n = 44)
Number of subjects: 93
Study 27549242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 47)
Number of subjects: 93
Study 27549242 — intervention group
Group type: EXPERIMENTAL
Intervention: Ramucirumab (n = 20)
Number of subjects: 93
Study 27549242 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 22)
Number of subjects: 93
Study 24273137 — intervention group
Group type: EXPERIMENTAL
Intervention: ICIQ‐UI SF
Number of subjects: 0
Study 24244725 — intervention group
Group type: EXPERIMENTAL
Intervention: Migraineurs
Number of subjects: 25
Study 24244725 — intervention group
Group type: COMPARATOR
Intervention: Non-migraine controls
Number of subjects: 25
Study 21846401 — intervention group
Group type: EXPERIMENTAL
Intervention: Integrated approach to care based on the chronic care model
Number of subjects: 30000
Study 21846401 — intervention group
Group type: EXPERIMENTAL
Intervention: Shared decision making intervention
Number of subjects: 30000
Study 21846401 — intervention group
Group type: EXPERIMENTAL
Intervention: School based care intervention through case management
Number of subjects: 30000
Study 21846401 — intervention group
Group type: COMPARATOR
Intervention: Usual care control group without electronic medical record (EMR)
Number of subjects: 30000
Study 21846401 — intervention group
Group type: COMPARATOR
Intervention: Control group with EMR with decision support, asthma action plans, and population reports at baseline
Number of subjects: 30000
Study 18234120 — intervention group
Group type: EXPERIMENTAL
Intervention: Olanzapine (1.25 mg/day for 3 days, 2.5 mg/day for 4 days, 5 mg/day for 1 week, then 7.5 mg/day for 10 weeks, followed by tapering over 2 weeks)
Number of subjects: 67
Study 18234120 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study 15740485 — intervention group
Group type: EXPERIMENTAL
Intervention: Fiber free (FF)
Number of subjects: 8
Study 15740485 — intervention group
Group type: EXPERIMENTAL
Intervention: Insoluble fiber (IF)
Number of subjects: 8
Study 15740485 — intervention group
Group type: EXPERIMENTAL
Intervention: Mixed fiber (MF)
Number of subjects: 8
Study 12431971 — intervention group
Group type: EXPERIMENTAL
Intervention: Postoperative radiotherapy (RT)
Number of subjects: 190
Study 10486668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure target < or = 80 mmHg (n = 6,262)
Number of subjects: 18790
Study 10486668 — intervention group
Group type: EXPERIMENTAL
Intervention: Diastolic blood pressure decrease from 90 to 80 mmHg in diabetic population
Number of subjects: 18790
Study 10486668 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetyl salicylic acid in well-controlled blood pressure population
Number of subjects: 18790
Study 10486668 — intervention group
Group type: COMPARATOR
Intervention: Diastolic blood pressure target < or = 85 mmHg (n = 6,264)
Number of subjects: 18790
Study 10486668 — intervention group
Group type: COMPARATOR
Intervention: Diastolic blood pressure target < or = 90 mmHg (n = 6,264)
Number of subjects: 18790
Study 8701855 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan 100 mg once daily
Number of subjects: 338
Study 8701855 — intervention group
Group type: EXPERIMENTAL
Intervention: Flosequinan 75 mg twice daily
Number of subjects: 338
Study 8701855 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 338
Study 1876437 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930 (15 mg daily)
Number of subjects: 204
Study 1876437 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930 (25 mg daily)
Number of subjects: 204
Study 1876437 — intervention group
Group type: EXPERIMENTAL
Intervention: ICS 205-930 (50 mg daily)
Number of subjects: 204
Study 1876437 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 204
Study 6639234 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine with epinephrine
Number of subjects: 14
Study 6639234 — intervention group
Group type: COMPARATOR
Intervention: Lidocaine alone
Number of subjects: 14
Study 31790519 — intervention group
Group type: EXPERIMENTAL
Intervention: Depression screening after acute coronary syndromes
Number of subjects: 0
Study 31790519 — intervention group
Group type: COMPARATOR
Intervention: Control group (no depression screening)
Number of subjects: 0
Study 29243411 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle aspiration (EUS-FNA)
Number of subjects: 23
Study 29243411 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS-guided fine-needle biopsy (EUS-FNB)
Number of subjects: 23
Study 27101760 — intervention group
Group type: EXPERIMENTAL
Intervention: Choline-enriched structured lipid (LYM-X-SORB)
Number of subjects: 110
Study 27101760 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 110
Study 23590972 — intervention group
Group type: EXPERIMENTAL
Intervention: Separation from a parent in childhood
Number of subjects: 781
Study 23590972 — intervention group
Group type: EXPERIMENTAL
Intervention: Death of a parent in childhood
Number of subjects: 781
Study 22416798 — intervention group
Group type: EXPERIMENTAL
Intervention: darunavir/ritonavir monotherapy
Number of subjects: 156
Study 22416798 — intervention group
Group type: COMPARATOR
Intervention: darunavir/ritonavir plus nucleoside reverse transcriptase inhibitors (triple therapy)
Number of subjects: 156
Study 20848004 — intervention group
Group type: EXPERIMENTAL
Intervention: Resin-modified glass ionomer cement (RMGIC) (Vitremer™, 3M ESPE)
Number of subjects: 320
Study 20848004 — intervention group
Group type: COMPARATOR
Intervention: Conventional light-cure, resin-based fissure sealant (LCRB) (Fluoroshield®, Dentsply Caulk)
Number of subjects: 320
Study 16402257 — intervention group
Group type: EXPERIMENTAL
Intervention: Colon dissection approach
Number of subjects: 21
Study 16402257 — intervention group
Group type: COMPARATOR
Intervention: Endoluminal view
Number of subjects: 21
Study 12621364 — intervention group
Group type: EXPERIMENTAL
Intervention: Growth hormone therapy
Number of subjects: 0
Study 12621364 — intervention group
Group type: EXPERIMENTAL
Intervention: Mannan-binding lectin (MBL) levels
Number of subjects: 0
Study 10781119 — intervention group
Group type: EXPERIMENTAL
Intervention: LMA‐High (fully inflated cuff)
Number of subjects: 160
Study 10781119 — intervention group
Group type: COMPARATOR
Intervention: LMA‐Low (semi‐inflated cuff)
Number of subjects: 160
Study 8978881 — intervention group
Group type: EXPERIMENTAL
Intervention: Low fat, increased fruit/vegetable/grain product intervention
Number of subjects: 2208
Study 8978881 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 2208
Study 1297667 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal resection involving 2/3rds of the vagina
Number of subjects: 154
Study 1297667 — intervention group
Group type: COMPARATOR
Intervention: Control group (vaginal resection not involving 2/3rds of the vagina)
Number of subjects: 154
Study 4006483 — intervention group
Group type: EXPERIMENTAL
Intervention: Beta-Blocker Heart Attack Trial (BHAT)
Number of subjects: 3837
Study 4006483 — intervention group
Group type: EXPERIMENTAL
Intervention: Hypertension Detection and Follow-up Program (HDFP)
Number of subjects: 3837
Study 31078823 — intervention group
Group type: EXPERIMENTAL
Intervention: Direct placement
Number of subjects: 60
Study 31078823 — intervention group
Group type: COMPARATOR
Intervention: Conventional placement
Number of subjects: 60
Study 28980306 — intervention group
Group type: EXPERIMENTAL
Intervention: 50% oxygen inhalation
Number of subjects: 120
Study 28980306 — intervention group
Group type: COMPARATOR
Intervention: Air inhalation
Number of subjects: 120
Study 27002448 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulindac (150 mg twice daily) and Erlotinib (75 mg daily)
Number of subjects: 92
Study 27002448 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 92
Study 24910380 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-directed exercise program
Number of subjects: 711
Study 24910380 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-administered stress management program
Number of subjects: 711
Study 24910380 — intervention group
Group type: EXPERIMENTAL
Intervention: Both self-directed exercise and stress management programs
Number of subjects: 711
Study 24910380 — intervention group
Group type: COMPARATOR
Intervention: Neither intervention (control group)
Number of subjects: 711
Study 22326977 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous sodium valproate
Number of subjects: 60
Study 22326977 — intervention group
Group type: COMPARATOR
Intervention: Intravenous phenobarbital
Number of subjects: 60
Study 19473858 — intervention group
Group type: EXPERIMENTAL
Intervention: articaine 20mg/ml
Number of subjects: 150
Study 19473858 — intervention group
Group type: EXPERIMENTAL
Intervention: articaine 40mg/ml
Number of subjects: 150
Study 19473858 — intervention group
Group type: COMPARATOR
Intervention: lidocaine 20mg/ml
Number of subjects: 150
Study 17988906 — intervention group
Group type: EXPERIMENTAL
Intervention: Collar graft
Number of subjects: 40
Study 17988906 — intervention group
Group type: COMPARATOR
Intervention: Standard dacron graft
Number of subjects: 40
Study 16202957 — intervention group
Group type: EXPERIMENTAL
Intervention: Analgesia or sedation during reduction of incarcerated inguinal hernia; 96.7% (245/253) of responders reported using analgesia or sedation.
Number of subjects: 331
Study 16202957 — intervention group
Group type: COMPARATOR
Intervention: Intravenous drugs used by pediatric surgeons; they were more likely to use intravenous drugs compared to pediatric emergency physicians.
Number of subjects: 331
Study 16202957 — intervention group
Group type: COMPARATOR
Intervention: Clinically related variables for pediatric emergency physicians; more important for PEPs than PS for analgesia and sedation.
Number of subjects: 331
Study 11898704 — intervention group
Group type: EXPERIMENTAL
Intervention: Vaginal solution 40 mg of phentolamine
Number of subjects: 41
Study 11898704 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral tablet 40 mg of phentolamine
Number of subjects: 41
Study 11898704 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 9895068 — intervention group
Group type: EXPERIMENTAL
Intervention: Sympathectomy (lidocaine injection into the brachial plexus)
Number of subjects: 0
Study 9895068 — intervention group
Group type: COMPARATOR
Intervention: Isotonic sodium chloride solution injection (placebo)
Number of subjects: 0
Study 9895068 — intervention group
Group type: EXPERIMENTAL
Intervention: tcPCO2
Number of subjects: 0
Study 7675689 — intervention group
Group type: EXPERIMENTAL
Intervention: Belief and information interventions
Number of subjects: 0
Study 7675689 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 0
Study 2048663 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxapram
Number of subjects: 0
Study 2048663 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 7297411 — intervention group
Group type: EXPERIMENTAL
Intervention: Naltrexone (dosage schedule used for opiate-dependent persons)
Number of subjects: 20
Study 7297411 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone (50 or 100 mg)
Number of subjects: 20
Study 7297411 — intervention group
Group type: COMPARATOR
Intervention: Naltrexone placebo
Number of subjects: 20
Study 30576726 — intervention group
Group type: EXPERIMENTAL
Intervention: Memory-game with images of vegetables (n=47)
Number of subjects: 100
Study 30576726 — intervention group
Group type: COMPARATOR
Intervention: Control group (memory-game with non-food items, n=53)
Number of subjects: 100
Study 28042930 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-group (three days sick leave)
Number of subjects: 0
Study 28042930 — intervention group
Group type: COMPARATOR
Intervention: 7D-group (seven days sick leave)
Number of subjects: 0
Study 28042930 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D-group
Number of subjects: 0
Study 28042930 — intervention group
Group type: COMPARATOR
Intervention: 7D-group
Number of subjects: 0
Study 25846055 — intervention group
Group type: EXPERIMENTAL
Intervention: Delayed-release 6-mercaptopurine (DR-6MP)
Number of subjects: 70
Study 25846055 — intervention group
Group type: COMPARATOR
Intervention: Purinethol (systemically delivered 6-mercaptopurine)
Number of subjects: 70
Study 24083231 — intervention group
Group type: EXPERIMENTAL
Intervention: One set of resistance training (n = 8)
Number of subjects: 16
Study 24083231 — intervention group
Group type: EXPERIMENTAL
Intervention: Three sets of resistance training (n = 8)
Number of subjects: 16
Study 21856517 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling sessions on breastfeeding directed toward both mother and grandmother (cohabitating group)
Number of subjects: 0
Study 21856517 — intervention group
Group type: EXPERIMENTAL
Intervention: Counseling sessions on breastfeeding directed only toward mother (not cohabitating group)
Number of subjects: 0
Study 21856517 — intervention group
Group type: COMPARATOR
Intervention: Control group (mother and grandmother not cohabitating, without intervention)
Number of subjects: 0
Study 21856517 — intervention group
Group type: COMPARATOR
Intervention: Control group (mother and grandmother cohabitating, without intervention)
Number of subjects: 0
Study 20025364 — intervention group
Group type: EXPERIMENTAL
Intervention: SM plus strategy increase (SI)
Number of subjects: 177
Study 20025364 — intervention group
Group type: EXPERIMENTAL
Intervention: SM plus alcohol reduction (AR)
Number of subjects: 177
Study 20025364 — intervention group
Group type: COMPARATOR
Intervention: SM control (SM)
Number of subjects: 177
Study 17088500 — intervention group
Group type: EXPERIMENTAL
Intervention: Sustained sadness state
Number of subjects: 14
Study 17088500 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral state
Number of subjects: 14
Study 12775457 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with myocardial infarction (MI)
Number of subjects: 50
Study 12775457 — intervention group
Group type: EXPERIMENTAL
Intervention: Patients with ventricular tachycardia (VT)
Number of subjects: 50
Study 12775457 — intervention group
Group type: COMPARATOR
Intervention: Normal individuals
Number of subjects: 50
Study 11044647 — intervention group
Group type: EXPERIMENTAL
Intervention: Information provided to patients regarding clinical trial participation
Number of subjects: 299
Study 11044647 — intervention group
Group type: EXPERIMENTAL
Intervention: Method of treatment allocation
Number of subjects: 299
Study 11044647 — intervention group
Group type: EXPERIMENTAL
Intervention: Written information
Number of subjects: 299
Study 11044647 — intervention group
Group type: EXPERIMENTAL
Intervention: Time for decision-making
Number of subjects: 299
Study 11044647 — intervention group
Group type: EXPERIMENTAL
Intervention: Satisfaction with decision to participate
Number of subjects: 299
Study 9084897 — intervention group
Group type: EXPERIMENTAL
Intervention: 5% CO2 inhalation with epinephrine
Number of subjects: 0
Study 9084897 — intervention group
Group type: COMPARATOR
Intervention: 5% CO2 inhalation with saline infusions
Number of subjects: 0
Study 8471439 — intervention group
Group type: EXPERIMENTAL
Intervention: Cooper type regimens containing doxorubicin hydrochloride (dox)
Number of subjects: 0
Study 8471439 — intervention group
Group type: COMPARATOR
Intervention: Cooper type regimens without doxorubicin (replaced by one or more compounds)
Number of subjects: 0
Study 3545034 — intervention group
Group type: EXPERIMENTAL
Intervention: Diltiazem (240 mg/day)
Number of subjects: 41
Study 3545034 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol (160 mg/day)
Number of subjects: 41
Study 3545034 — intervention group
Group type: EXPERIMENTAL
Intervention: Molsidomine (8 mg/day)
Number of subjects: 41
Study 31034730 — intervention group
Group type: EXPERIMENTAL
Intervention: Quadratus lumborum block
Number of subjects: 44
Study 31034730 — intervention group
Group type: COMPARATOR
Intervention: Caudal block
Number of subjects: 44
Study 31034730 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 44
Study 29105211 — intervention group
Group type: EXPERIMENTAL
Intervention: Parent-focused family-based treatment (PFT)
Number of subjects: 153
Study 29105211 — intervention group
Group type: COMPARATOR
Intervention: Conjoint family-based treatment (FBT)
Number of subjects: 153
Study 29105211 — intervention group
Group type: EXPERIMENTAL
Intervention: Maternal expressed emotion (EE)
Number of subjects: 153
Study 29105211 — intervention group
Group type: EXPERIMENTAL
Intervention: Paternal expressed emotion (EE)
Number of subjects: 153
Study 25751130 — intervention group
Group type: EXPERIMENTAL
Intervention: Beck Scale for Suicide Ideation (21 items)
Number of subjects: 301
Study 25751130 — intervention group
Group type: COMPARATOR
Intervention: Quality of Life (19 items)
Number of subjects: 301
Study 24521561 — intervention group
Group type: EXPERIMENTAL
Intervention: Ancient wheat products (bread, pasta, biscuits and crackers) for 6 weeks
Number of subjects: 20
Study 24521561 — intervention group
Group type: COMPARATOR
Intervention: Modern wheat products (bread, pasta, biscuits and crackers) for 6 weeks
Number of subjects: 20
Study 22901350 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine
Number of subjects: 227
Study 22901350 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 227
Study 22901350 — intervention group
Group type: EXPERIMENTAL
Intervention: Agomelatine (in severe patients)
Number of subjects: 227
Study 20568829 — intervention group
Group type: COMPARATOR
Intervention: Moxifloxacin 400 mg (positive control)
Number of subjects: 84
Study 20568829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 4 mg/kg alone
Number of subjects: 84
Study 20568829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 32 mg/kg alone
Number of subjects: 84
Study 20568829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 32 mg/kg with rocuronium 1.2 mg/kg
Number of subjects: 84
Study 20568829 — intervention group
Group type: EXPERIMENTAL
Intervention: Sugammadex 32 mg/kg with vecuronium 0.1 mg/kg
Number of subjects: 84
Study 18334007 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly topotecan (4 mg/m(2))
Number of subjects: 39
Study 15681250 — intervention group
Group type: EXPERIMENTAL
Intervention: Steroid injection
Number of subjects: 30
Study 12105829 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS staging
Number of subjects: 80
Study 12105829 — intervention group
Group type: COMPARATOR
Intervention: CT staging
Number of subjects: 80
Study 12105829 — intervention group
Group type: EXPERIMENTAL
Intervention: EUS FNA
Number of subjects: 80
Study 12205257 — intervention group
Group type: EXPERIMENTAL
Intervention: HOPE-ROP infants
Number of subjects: 136
Study 12205257 — intervention group
Group type: COMPARATOR
Intervention: STOP-ROP infants
Number of subjects: 136
Study 9713056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YLF ps laser for iridectomies (n=53)
Number of subjects: 70
Study 9713056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YLF ps laser for capsulotomies (n=9)
Number of subjects: 70
Study 9713056 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG ns laser for capsulotomies (n=10)
Number of subjects: 70
Study 9713056 — intervention group
Group type: COMPARATOR
Intervention: Nd:YAG ns laser for iridotomies (n=20)
Number of subjects: 70
Study 9713056 — intervention group
Group type: EXPERIMENTAL
Intervention: Nd:YLF ps laser for vitreoretinal applications (n=2)
Number of subjects: 70